The Nikkei has reported that Japan is in talks with the UK, France & other potential partners to jointly buy coronavirus vaccine.
The Nikkei wrote, "the nations aim to establish the purchasing program as soon as this summer, with Japan expected to contribute as much as $800 million or so, according to people familiar with the matter."
Lead paragraphs
As the US and China race to secure stable vaccine supplies for their own populations, Japan and European countries see an advantage in combining their lesser financial resources.
Around 30 nations have said they intend to join the joint purchases, including Italy, Spain, Norway and Canada. The European Union is also involved in the talks. Participating countries would agree to take no more than enough coronavirus vaccine for 20% of their population.
Market implications
Meanwhile, researchers around the world are developing more than 145 vaccines against coronavirus.
There are currently 21 vaccines are in human trials according to the New Your Times vaccine tracker.
Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective vaccine by next year.
There is a major focus on the spread of the virus in the US and questions over whether the US can contain the contagion in what Dr. Anthony Fauci, one of the nation's leading experts on infectious diseases, says that the US is knee-deep in the first wave.
However, in other news, Dr. Anthony Fauci, one of the nation's leading experts on infectious diseases, warned Sunday that it's "unlikely" the US will achieve herd immunity to the coronavirus if a portion of the population refuses to get a coronavirus vaccine.
Fauci said he would "settle" for a coronavirus vaccine that is between 70% and 75% effective, "because that would bring you to that level that would be herd immunity level."
However, in ear;lier interviews, Fauci said he worried about the “durability” of a potential coronavirus vaccine.
CNBC reported him saying that there’s a chance it may not provide long-term immunity.
If Covid-19 acts like other coronaviruses, 'it likely isn’t going to be a long duration of immunity,' Fauci, director of the National Institute of Allergy and Infectious Diseases, told JAMA Editor Howard Bauchner.
Nevertheless, the stock markets are weathering the tail risks well, so far, but gold is compelling this week as it embarks of a break into the $1,800s.
With 10y breakevens continuing to print new post-COVID highs, the normalization in inflation expectations may remain a powerful driver lifting gold prices deeper into $1,800/oz territory,
analysts at TD Securities explained.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD clings to daily gains above 1.0650
EUR/USD gained traction and turned positive on the day above 1.0650. The improvement seen in risk mood following the earlier flight to safety weighs on the US Dollar ahead of the weekend and helps the pair push higher.
GBP/USD recovers toward 1.2450 after UK Retail Sales data
GBP/USD reversed its direction and advanced to the 1.2450 area after touching a fresh multi-month low below 1.2400 in the Asian session. The positive shift seen in risk mood on easing fears over a deepening Iran-Israel conflict supports the pair.
Gold holds steady at around $2,380 following earlier spike
Gold stabilized near $2,380 after spiking above $2,400 with the immediate reaction to reports of Israel striking Iran. Meanwhile, the pullback seen in the US Treasury bond yields helps XAU/USD hold its ground.
Bitcoin Weekly Forecast: BTC post-halving rally could be partially priced in Premium
Bitcoin price shows no signs of directional bias while it holds above $60,000. The fourth BTC halving is partially priced in, according to Deutsche Bank’s research.
Week ahead – US GDP and BoJ decision on top of next week’s agenda
US GDP, core PCE and PMIs the next tests for the Dollar. Investors await BoJ for guidance about next rate hike. EU and UK PMIs, as well as Australian CPIs also on tap.